September 19, 2016 11:19 AM EDT

GE blueprints $165M biologics facilities; Tarveda to partner with Madrigal in $163M deal

John Carroll

Editor & Founder

GE Healthcare, which has been focusing on reengineering the way biologics are made, is investing $165 million in four turnkey “off the shelf” facilities …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GE blueprints $165M biologics facilities; Tarveda to partner with Madrigal in $163M deal

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Outlook's shares crash as wet AMD drug flunks Phase 3 test

GE blue­prints $165M bi­o­log­ics fa­cil­i­ties; Tarve­da to part­ner with Madri­gal in $163M deal

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

GE blueprints $165M biologics facilities; Tarveda to partner with Madrigal in $163M deal

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Outlook's shares crash as wet AMD drug flunks Phase 3 test